References
- Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. Q J Med. 1999;92:211–8.
- Austin HA III, Klippel JH, Balow JE, Le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled trial of prednisolone and cytotoxic drugs. N Engl J Med. 1986;314:614–9.
- Boumpas DT, Austin HA III, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednis-olone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992;340:741–5.
- Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum. 1991;21: 55–64.
- Mizuno K, Tsujino M, Takada M, Hayashi M, Atsumi K. Studies on bredinin. I. Isolation, characterization and biological proper-ties. J Antibiot. 1974;27:775–82.
- Turka LA, Dayton J, Sinclair G, Thompson CB, Mitchell BS. Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest. 1991;87:940–8.
- Hughes SE, Gruber SA. New immunosuppressive drugs in organ transplantation. J Clin Pharmacol. 1996;36:1081–92.
- Kawasaki Y, Suzuki J, Sakai N, Etoh S, Murai H, Nozawa R, et al. Efficacy of prednisolone and mizoribine therapy for diffuse IgA nephropathy. Am J Nephrol. 2004;24:147–53.
- Tanaka H, Abe T, Nishimura S, Sakai H, Kimura H, Old M, et al. A case of rheumatoid arthritis/Sjogren's syndrome with acute renal failure due to hyperuricemia associated with mizoribine therapy (in Japanese). Jpn J Clin Immunol. 2004;27:171–6.
- Yumura W, Suganuma S, Uchida K, Moriyama T, Otsubo S, Takei T, et al. Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis. Clin Nephrol. 2005;64:28–34.
- Hamasaki T, Mori M, Kinoshita Y, Saeki T, Sakano T. Mizori-bine in steroid-dependent nephrotic syndrome of childhood. Pediatr Nephrol. 1997;11:625–7.
- Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int. 2000;58:317–24.
- Sonda K, Takahashi K, Tanabe K, Funchinoue S, Hayasaka Y, Kawaguchi H, et al. Clinical pharmacokinetic study of miz-oribine in renal transplantation patients. Transplant Proc. 1996;28:3643–8.
- Honda M. Nephrotic syndrome and mizoribine in children. Pediatr Int. 2002;44:210–6.
- Abe Y, Tsuji Y, Hisano M, Nakada M, Miura K, Watanabe S, et al. Pharmacokinetic study of mizoribine in an adolescent with lupus nephritis. Pediatr Int. 2004;46:597–600.
- Tanaka H, Suzuki K, Nakahata T, Sato T, Ito E. Mizoribine oral pulse therapy for a patient with severe lupus nephritis. Pediatr Int. 2003;45:488–90.
- Kuroda T, Hirose S, Tanabe N, Sato H, Nakatsue T, Ajiro J, et al. Mizoribine therapy for patients with lupus nephritis: the associ-ation between peak mizoribine concentration and clinical efficacy. Mod Rheumatol. 2007;17:206–12.
- Kamata K, Okubo M, Ishigamori E, Masaki Y, Uchida H, Watanabe K, et al. Immunosuppressive effect of bredinin on cell-mediated and humoral immune reactions in experimental ani-mals. Transplantation. 1983;35:144–9.
- Okubo M, Chen XM, Kamata K, Masaki Y, Uchiyama T. Sup-pressive effect of mizoribine on humoral antibody production in DBA/2 mice. Transplantation. 1986;41: 495–8.
- Kamata K, Okubo M, Uchiyama T, Masaki Y, Kobayashi Y, Tanaka T. Effect of mizoribine on lupus nephropathy of New Zealand black/white Fl hybrid mice. Clin Immunol Immunopa-thol. 1984;33:31–8.
- Mitarai T, Kasahara N, Katoh H, Kawamura T, Takahashi T. Effects of glucocorticoid and immunosuppressants on glomerular endothelial cells and mesangial cells (in Japanese). Saishin Igaku. 1993;48:1397–403.
- Takahashi S, Wakui H, Gustafsson JA, Zilliacus J, Itoh H. Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun. 2000;274: 87–92.